ClinicalTrials.gg
CompletedNCT02068222Updated Feb 22, 2018Results posted

A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

A Phase 2 interventional study of ABT-450/ritonavir (r) and ABT-530 in Chronic Hepatitis C and Hepatitis C Virus, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-02-22.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing paritaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. paritaprevir · Hepatitis C, Chronic.

Enrollment
15th of 16
10 · median 124
Started
2014
the only one that year
Phase 2
5 of 16
none open now
Registered
7th of 16
by date
Lead sponsor
9 of 16
AbbVie

Among the 16 studies testing paritaprevir in Hepatitis C, Chronic, this one is the 15th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 2, and was the 7th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 16 studies testing paritaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

Where they have run

About paritaprevir

paritaprevir: first FDA approval 2015 (TECHNIVIE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing paritaprevir in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of this study is to evaluate the safety and antiviral effect of ABT-450/r and ABT-530 coadministered with and without Ribavirin in adults with genotype 3 HCV infection.

Read the detailed description

Once the efficacy and safety data were obtained from participants administered ABT-450/r + ABT-530 + RBV weight-based (Arm 1) in Study M14-213, the decision was made to end this study before subjects were enrolled into Arm 2.

03

Conditions studied

  • Chronic Hepatitis C
  • Hepatitis C Virus

Keywords

  • Hepatitis C
  • HCV
  • Interferon Free
  • Chronic Hepatitis C
  • Hepatitis C virus
  • Hepatitis C Genotype 3
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (of non-child bearing potential) between 18 and 70 years of age with ≥18 to \<38 kg/m2.
  • Chronic genotype 3 infection prior to study enrollment and has never received antiviral treatment for HCV.
  • Subject has plasma HCV RNA level > 10,000 IU/mL at Screening.
  • Sexually active males must be sterile, have male partners only, or agree to use two effective forms of for 7 months after stopping study drug.

Exclusion criteria

Exclusion Criteria:

  • History of severe, life-threatening or other significant sensitivity to any drug.
  • Positive test result for surface antigen (HBsAg) or anti- antibody (HIV Ab).
  • Prior therapy for the treatment of .
  • Any current or past clinical evidence of cirrhosis.
  • Any cause of liver disease other than chronic HCV-infection.
  • HCV genotype co-infection with any other HCV genotype.
  • Use of medications within 2 weeks or 10 half-lives of dosing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    ABT-450/r and ABT-530 plus RBV

    ABT-450/r (150 mg/100 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

    Drug: ABT-450/ritonavir (r) · Drug: ABT-530 · Drug: Ribavirin (RBV)

Interventions

06

What researchers measure

Primary outcomes

  1. The Percentage of Subjects Who Achieve 12-week Sustained Virologic Response (SVR12)

    SVR12 defined as hepatitis C (HCV) ribonucleic acid (RNA) less than the lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.

    Time frame: 12 weeks after last dose of study drug

Secondary outcomes

  1. The Percentage of Subjects Who Achieve 24-week Sustained Virologic Response (SVR24)

    SVR24 defined as HCV RNA LLOQ 24 weeks after last dose of study drug.

    Time frame: 24 weeks after last dose of study drug

  2. The Percentage of Subjects With Virologic Failure During Treatment

    Percentage of subjects with quantifiable HCV RNA throughout the entire treatment period, confirmed quantifiable HCV RNA after previously having unquantifiable HCV RNA, or a confirmed increase of at least one log10 in HCV RNA during treatment.

    Time frame: Up to Treatment Week 12

  3. The Percentage of Subjects With Post-Treatment Relapse

    Percentage of subjects with confirmed quantifiable HCV RNA within 12 weeks of last dose among subjects with unquantifiable hepatitis C virus ribonucleic acid at the end of treatment.

    Time frame: Within 12 weeks after the last dose of study drug

07

Results

Posted Feb 2, 2017

Participant flow

Participant flow — Overall Study
MilestoneABT-450/r and ABT-530 Plus RBV
Started10
Completed9
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryThe Percentage of Subjects Who Achieve 12-week Sustained Virologic Response (SVR12)

SVR12 defined as hepatitis C (HCV) ribonucleic acid (RNA) less than the lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.

Time frame:
12 weeks after last dose of study drug
Reported as:
Number · percentage of participants
The Percentage of Subjects Who Achieve 12-week Sustained Virologic Response (SVR12)
percentage of participantsABT-450/r and ABT-530 Plus RBV
The Percentage of Subjects Who Achieve 12-week Sustained Virologic Response (SVR12)90 (55.5 to 99.7)
SecondaryThe Percentage of Subjects Who Achieve 24-week Sustained Virologic Response (SVR24)

SVR24 defined as HCV RNA LLOQ 24 weeks after last dose of study drug.

Time frame:
24 weeks after last dose of study drug
Reported as:
Number · percentage of participants
The Percentage of Subjects Who Achieve 24-week Sustained Virologic Response (SVR24)
percentage of participantsABT-450/r and ABT-530 Plus RBV
The Percentage of Subjects Who Achieve 24-week Sustained Virologic Response (SVR24)90 (55.5 to 99.7)
SecondaryThe Percentage of Subjects With Virologic Failure During Treatment

Percentage of subjects with quantifiable HCV RNA throughout the entire treatment period, confirmed quantifiable HCV RNA after previously having unquantifiable HCV RNA, or a confirmed increase of at least one log10 in HCV RNA during treatment.

Time frame:
Up to Treatment Week 12
Reported as:
Number · percentage of participants
The Percentage of Subjects With Virologic Failure During Treatment
percentage of participantsABT-450/r and ABT-530 Plus RBV
The Percentage of Subjects With Virologic Failure During Treatment10 (0.3 to 44.5)
SecondaryThe Percentage of Subjects With Post-Treatment Relapse

Percentage of subjects with confirmed quantifiable HCV RNA within 12 weeks of last dose among subjects with unquantifiable hepatitis C virus ribonucleic acid at the end of treatment.

Time frame:
Within 12 weeks after the last dose of study drug
Reported as:
Number · percentage of participants
The Percentage of Subjects With Post-Treatment Relapse
percentage of participantsABT-450/r and ABT-530 Plus RBV
The Percentage of Subjects With Post-Treatment Relapse0 (0.0 to 0.0)

Adverse events

Collected over Treatment-emergent AEs (TEAEs) were collected from first dose of study drug until 30 days after the last dose of study drug (up to 16.5 weeks); serious adverse events (SAEs) were collected from the time informed consent was obtained through end of study (up to 41 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABT-450/r and ABT-530 Plus RBV—0/10 (0%)9/10 (90%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventABT-450/r and ABT-530 Plus RBV
FATIGUEGeneral disorders4/10
DYSPNOEARespiratory, thoracic and mediastinal disorders3/10
NAUSEAGastrointestinal disorders2/10
MYALGIAMusculoskeletal and connective tissue disorders2/10
DIZZINESSNervous system disorders2/10
RASHSkin and subcutaneous tissue disorders2/10
ANAEMIABlood and lymphatic system disorders1/10
DRY EYEEye disorders1/10
DIARRHOEAGastrointestinal disorders1/10
FAECES SOFTGastrointestinal disorders1/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)ABT-450/r and ABT-530 Plus RBV
Mean52.5 ± 10.19
Sex: Female, Male
Sex: Female, Male(Participants)ABT-450/r and ABT-530 Plus RBV
Female2
Male8
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Poordad F, Landis CS, Asatryan A, Jackson DF 3rd, Ng TI, Fu B, Lin CW, Yao B, Kort J. High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver Int. 2016 Aug;36(8):1125-32. doi: 10.1111/liv.13067. Epub 2016 Feb 3. PubMed 26778412 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 1 year 11 months after primary completion. A results delay was requested in Mar 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2014
First posted
Feb 21, 2014
Start
Apr 2014
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results delay requested
Mar 3, 2016
Results first posted
Feb 2, 2017
Last update
Feb 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02068222
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 21, 2014
Start date
Apr 2014
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Feb 2, 2017
Last update
Feb 22, 2018

Study contacts

Armen Asatryan, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paritaprevir · Ritonavir · Pibrentasvir · Ribavirin

Start the discussion